AstraZeneca and Alexion will present at the International Symposium on Amyloidosis (ISA) 2024, showcasing studies on their amyloidosis treatment pipeline.
Key findings include subgroup analyses from the NEURO-TTRansform study of WAINUATM (eplontersen), which the FDA approved for treating the polyneuropathy of hereditary transthyretin-mediated amyloidosis.
Clinical data will also be presented on ALXN2220 and anselamimab, undergoing Phase III trials for ATTR and light chain (AL) amyloidosis.
AstraZeneca emphasizes its commitment to advancing amyloidosis research and improving patient outcomes. Alexion highlights the significance of its pipeline and ongoing efforts to develop multifaceted treatments for halting or reversing organ damage.
Additional presentations include live-cell imaging and Phase I data on ALXN2220’s ability to remove cardiac amyloid, supporting its potential use in advanced ATTR cardiomyopathy. Findings on epidemiology and patient renal outcomes will underscore the need for improved diagnosis and treatment options in AL amyloidosis.
AstraZeneca’s evidence program provides insights into patient characteristics and treatment effectiveness, including data on US patient characteristics and the MaesTTRo study design for assessing real-world effectiveness of treatments for ATTR.
WAINUA is also being evaluated in the CARDIO-TTRANSform study for adults with cardiomyopathy of transthyretin-mediated amyloidosis (ATTR-CM), a progressive and fatal condition. The Phase 3 study, with over 1,400 patients, is the largest in this patient population.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
